• Target：
• Galectin-8

• Gene Name：
• LGALS8

• Protein Name：
• Galectin-8

• Human Gene Id：
• 3964

• Human Swiss Prot No：
• O00214

• Mouse Gene Id：
• 56048

• Mouse Swiss Prot No：
• Q9JL15

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human LEG8. AA range:61-110

• Specificity：
• Galectin-8 Polyclonal Antibody detects endogenous levels of Galectin-8 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC: 1:100-300 ELISA: 1:20000. IF 1:100-300 Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• LGALS8;Galectin-8;Gal-8;Po66 carbohydrate-binding protein;Po66-CBP;Prostate carcinoma tumor antigen 1;PCTA-1

• Observed Band(KD)：
• 36kD

• Background：
• This gene encodes a member of the galectin family. Galectins are beta-galactoside-binding animal lectins with conserved carbohydrate recognition domains. The galectins have been implicated in many essential functions including development, differentiation, cell-cell adhesion, cell-matrix interaction, growth regulation, apoptosis, and RNA splicing. This gene is widely expressed in tumoral tissues and seems to be involved in integrin-like cell interactions. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008],

• Function：
• domain:Contains two homologous but distinct carbohydrate-binding domains.,online information:Galectin-8 C-terminal CRD,online information:Galectin-8 long isoform,similarity:Contains 2 galectin domains.,tissue specificity:Ubiquitous. Selective expression by prostate carcinomas versus normal prostate and benign prostatic hypertrophy.,

• Subcellular Location：
• Cytoplasmic vesicle . Cytoplasm, cytosol .

• Expression：
• Ubiquitous. Selective expression by prostate carcinomas versus normal prostate and benign prostatic hypertrophy.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs